Insulet's OmniPod

Company: Insulet ($PODD)
Device: OmniPod
Drug delivered: insulin

Why it's important: In the valuable diabetes market, one delivery device making headway is Insulet's next-gen OmniPod, the combination lightweight insulin pump and wireless glucometer. With FDA approval notched earlier this year, the first-of-its-kind tubing-free pump offers continuous glucose monitoring in a sleek design.

Having worked together with DexCom ($DXCM) since 2008, Insulet went its own way just before the FDA approved the OmniPod. But with its new, undisclosed partner, Insulet could make a run at Medtronic ($MDT); the company's Paradigm is the only other integrated insulin pump and glucose monitor currently on the market. Insulet's tubeless version, though, could be the one to watch.

By offering a more seamless alternative to traditional insulin pumps, the newest OmniPod has the potential to make a dent this year in the valuable diabetes market.

For more:
Special Report: Top 5 Insulin-Delivery Techs To Watch
FDA approves Insulet's next-gen OmniPod insulin device
Insulet ditches DexCom in diabetes collaboration

Insulet's OmniPod
Read more on

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.